Opinion

New research, involving 200 professionals in senior roles spanning pharmacovigilance (PV), Drug Safety and Product Safety departments, has found that quality has overtaken cost as a priority in plans for automating adverse event (AE) reporting. John Price, life sciences industry consultant and partner of Arriello, which commissioned this latest research, reports on the findings.  Although the Covid-19 pandemic has stalled progress with digital process […]

The Cell & Gene Collective publicly launched in May 2021. Lu Rahman caught up with Julian Cole, Country Medical Director of Gilead Sciences for the UK and Ireland to find out more about this cross-industry alliance between Astellas, bluebird bio, Bristol Myers Squibb, Kite (a Gilead company) and Novartis.  LR: What was the thinking behind the Collective? […]

Listen to this article on the DDW Podcast: John Couse, PhD, Vice President, Scientific Services, Taconic Biosciences, explains how focussing on best practices for animal models can reduce a project’s timeline, budget, and total number of animals used.   Research organisations engaged in drug discovery rely on animal models, including genetically engineered mice, to support and […]

Professor Paul Whiting, Chief Scientific Officer of The Alzheimer’s Research UK UCL Drug Discovery Institute (ARUK UCL DDI), and Stephane Martinez, product manager and neuroscience expert in PerkinElmer’s Life Sciences segment, share expert insights on Alzheimer’s Disease research today and where discovery and therapeutic approaches might be headed next.  Alzheimer’s disease (AD) is an irreversible […]

Listen to this article on the DDW Podcast:   Panna Sharma is the President and CEO of Lantern Pharma, a clinical-stage oncology biotech using AI and genomics to innovate the rescue, revitalisation, and development of precision cancer therapeutics. Lu Rahman spoke to the man behind this biotech to find out why he believes AI is about to […]

Doina Ionescu, General Manager for the UK & Ireland at Merck, talks with DDW’s Megan Thomas about Merck’s innovations in the oncology sector, her thoughts on the future opportunities in the sector, as well some trade secrets and more.  MT: The company has expertise in the oncology space – what innovations can you share and can you talk me […]

Listen to this article on the DDW Podcast: Dr Tomasz Kostrzewski, Director of Biology at CN Bio Innovations, examines MPS in drug discovery as part of a preclinical toolbox.  Drug development remains slow and costly for the pharmaceutical industry, driven by the financial impact of late-stage failures of drug candidates1. Although our understanding of the molecular […]

Megan Thomas, DDW, comments on her experience of ELRIG UK’s Drug Discovery 2021 Having started my role as Editorial Assistant at DDW during the pandemic – my first within the drug discovery industry – my instinct was, “what a time to be in the thick of it”. As 2021 unfolded, scientists developed Covid-19 vaccines which […]

The life sciences data landscape is growing in complexity and scale, with organisations generating increasingly high volumes of data. Yet, these data are still stored and searched using outdated methods. As a result, there are vast amounts of unstructured data stored in various siloed locations. Vladimir Makarov, Consultant at Pistoia Alliance, discusses this challenge and […]